RedChip Show to Feature Interviews with TMC and ASPI
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Should l Buy ASPI?
Source: Yahoo Finance
- TMC's Strategic Role: TMC CFO Craig Shesky emphasized the company's importance in addressing U.S. critical mineral dependence during the RedChip show, particularly through the development of polymetallic nodule resources in the Clarion Clipperton Zone, which could provide a long-term domestic supply of nickel, copper, cobalt, and manganese, thereby enhancing the U.S.'s strategic position amid geopolitical competition.
- Regulatory Framework Progress: Shesky noted TMC's advancements under the U.S. Deep Seabed Hard Mineral Resources Act and updates to NOAA's permitting process, which streamline the path toward commercial recovery, facilitating rapid growth in the critical minerals sector.
- ASPI's Market Positioning: ASP Isotopes CEO Paul Mann discussed the company's vertically integrated strategy to become a leading Western supplier of critical stable isotopes and nuclear fuels, highlighting the increasing importance of ASPI amid global supply concentration, particularly Russia's dominance in stable isotope production.
- Revenue Growth Potential: Mann pointed out that ASPI's nuclear medicine platform is generating double-digit year-over-year revenue growth, and the recent acquisition of Renergen provides access to one of the world's most concentrated helium resources, with 2026 poised to be a transformational year for the company as it advances toward scaled commercial production across multiple high-value critical material markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASPI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASPI
Wall Street analysts forecast ASPI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.110
Low
11.00
Averages
12.00
High
13.00
Current: 5.110
Low
11.00
Averages
12.00
High
13.00
About ASPI
ASP Isotopes Inc. is a development stage advanced materials company. The Company is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100, and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ASP Isotopes Stock Rises on Nuclear Energy Agreement
- Stock Surge: ASP Isotopes Inc. (NASDAQ:ASPI) shares rose 6.65% to $5.45 today after announcing a non-binding memorandum of understanding with a large U.S. energy company, indicating strong market optimism regarding future collaborations.
- Annual Performance: The stock has increased by 37.19% over the past year, although it remains closer to its 52-week low than its high, suggesting that investor interest in the company's nuclear energy potential could drive future price recovery.
- Technical Indicator Analysis: Currently, ASPI is trading 2.8% above its 20-day simple moving average but 22.2% below its 100-day average, reflecting a short-term bounce while indicating that the long-term trend still requires improvement, prompting cautious investor sentiment.
- Future Earnings Outlook: The upcoming earnings report on March 30, 2026, is expected to show an EPS loss of 14 cents with revenue estimated at $2.03 million, up from $1.19 million year-over-year, suggesting that while profitability remains a challenge, market confidence in future growth may strengthen.
See More
Quantum Leap Energy Signs Agreement with Utility for Nuclear Fuel Production
- Nuclear Fuel Production Expansion: Quantum Leap Energy has signed a memorandum of understanding with an unnamed utility to develop advanced nuclear fuel cycle facilities in the U.S., focusing on producing high-assay low-enriched uranium (HALEU) and low-enriched uranium plus (LEU+), which are essential for next-generation reactors, thereby enhancing domestic nuclear fuel production capabilities.
- Supporting Future Reactor Designs: The agreement aims to support next-generation reactor technologies and is expected to supply LEU+ fuel to existing nuclear facilities currently using conventional low-enriched uranium, reflecting a commitment to strengthening domestic nuclear fuel production and reducing reliance on overseas suppliers.
- Rising Market Demand: As developers work on advanced reactors and small modular designs, the demand for enriched uranium is increasing, with industry participants and policymakers emphasizing the importance of bolstering domestic production to meet future energy needs.
- Positive Market Reaction: ASPI's stock rose 0.7% in Friday's premarket trading, and retail sentiment on Stocktwits shifted from 'bearish' to 'neutral', indicating growing market confidence in the company's future prospects.
See More
RedChip Show to Feature Interviews with TMC and ASPI
- TMC's Strategic Role: TMC CFO Craig Shesky emphasized the company's importance in addressing U.S. critical mineral dependence during the RedChip show, particularly through the development of polymetallic nodule resources in the Clarion Clipperton Zone, which could provide a long-term domestic supply of nickel, copper, cobalt, and manganese, thereby enhancing the U.S.'s strategic position amid geopolitical competition.
- Regulatory Framework Progress: Shesky noted TMC's advancements under the U.S. Deep Seabed Hard Mineral Resources Act and updates to NOAA's permitting process, which streamline the path toward commercial recovery, facilitating rapid growth in the critical minerals sector.
- ASPI's Market Positioning: ASP Isotopes CEO Paul Mann discussed the company's vertically integrated strategy to become a leading Western supplier of critical stable isotopes and nuclear fuels, highlighting the increasing importance of ASPI amid global supply concentration, particularly Russia's dominance in stable isotope production.
- Revenue Growth Potential: Mann pointed out that ASPI's nuclear medicine platform is generating double-digit year-over-year revenue growth, and the recent acquisition of Renergen provides access to one of the world's most concentrated helium resources, with 2026 poised to be a transformational year for the company as it advances toward scaled commercial production across multiple high-value critical material markets.
See More
Significant Progress in U.S. Nuclear Fuel Supply Chain
- Strategic Partnership: ASP Isotopes Inc.'s subsidiary Quantum Leap Energy has signed a non-binding MOU with a major U.S. energy company to evaluate options for supporting the establishment of advanced nuclear fuel cycle facilities in the U.S., thereby enhancing domestic nuclear fuel production capabilities.
- Nuclear Fuel Production Plans: Under the MOU, QLE plans to produce high assay low enriched uranium (HALEU) and low enriched uranium plus (LEU+), as well as provide uranium conversion and deconversion services, which will help meet the future demand for higher enrichment levels in small modular reactors, thus enhancing U.S. energy independence.
- Growing Market Demand: With the U.S. government planning to ban Russian uranium imports by 2028, the urgent need for domestic uranium enrichment capacity is increasing, and QLE's facilities are expected to fill a critical gap in the nuclear fuel supply chain, potentially having a profound impact on the future nuclear energy market.
- Technological Innovation and Collaboration: QLE is committed to accelerating the commercialization of critical isotopes through strategic partnerships with industry leaders, leveraging unique technological solutions to further advance U.S. competitiveness and innovation in the nuclear energy sector.
See More
Investigation into ASP Isotopes Inc. Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of ASP Isotopes Inc. (NASDAQ:ASPI) breached their fiduciary duties to shareholders, potentially impacting corporate governance.
- Legal Relief Options: Long-term shareholders of ASP stock may seek corporate governance reforms, return of funds, or court-approved financial incentive awards, which could improve management and transparency.
- Importance of Participation: Shareholder involvement can drive improvements in company policies, practices, and oversight mechanisms, enhancing transparency and accountability, ultimately increasing shareholder value.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, reducing the financial burden of participation.
See More
Shorepower Merges with Aeternum, Shifts Focus to Health Technologies
- Merger Agreement: Shorepower Technologies has signed a merger agreement with Aeternum Health, with Aeternum merging into Shorepower, which will shift its strategic focus to health optimization and longevity technologies, marking a significant change in the company's direction.
- Equity Structure Adjustment: Post-merger, the sole member of Aeternum Health will receive 51% of Shorepower's common stock, and 2 million shares of Series B Preferred Stock will be issued, each with voting power equivalent to 40 shares of common stock, enhancing the new management's control.
- Capital and Technology Injection: Aeternum will contribute at least $1.5 million in cash and intellectual property related to a novel peptide mix aimed at longevity and anti-aging, which is expected to enhance the company's competitive position in the market.
- Leadership Change: Following the merger, Jeff Kim will resign as President and CEO, with Paul E. Mann of Aeternum taking over, bringing over two decades of experience in biotechnology and healthcare investing, which is anticipated to open new growth opportunities for the company.
See More
ASP Isotopes Stock Rises on Nuclear Energy Agreement
- Stock Surge: ASP Isotopes Inc. (NASDAQ:ASPI) shares rose 6.65% to $5.45 today after announcing a non-binding memorandum of understanding with a large U.S. energy company, indicating strong market optimism regarding future collaborations.
- Annual Performance: The stock has increased by 37.19% over the past year, although it remains closer to its 52-week low than its high, suggesting that investor interest in the company's nuclear energy potential could drive future price recovery.
- Technical Indicator Analysis: Currently, ASPI is trading 2.8% above its 20-day simple moving average but 22.2% below its 100-day average, reflecting a short-term bounce while indicating that the long-term trend still requires improvement, prompting cautious investor sentiment.
- Future Earnings Outlook: The upcoming earnings report on March 30, 2026, is expected to show an EPS loss of 14 cents with revenue estimated at $2.03 million, up from $1.19 million year-over-year, suggesting that while profitability remains a challenge, market confidence in future growth may strengthen.
See More
Quantum Leap Energy Signs Agreement with Utility for Nuclear Fuel Production
- Nuclear Fuel Production Expansion: Quantum Leap Energy has signed a memorandum of understanding with an unnamed utility to develop advanced nuclear fuel cycle facilities in the U.S., focusing on producing high-assay low-enriched uranium (HALEU) and low-enriched uranium plus (LEU+), which are essential for next-generation reactors, thereby enhancing domestic nuclear fuel production capabilities.
- Supporting Future Reactor Designs: The agreement aims to support next-generation reactor technologies and is expected to supply LEU+ fuel to existing nuclear facilities currently using conventional low-enriched uranium, reflecting a commitment to strengthening domestic nuclear fuel production and reducing reliance on overseas suppliers.
- Rising Market Demand: As developers work on advanced reactors and small modular designs, the demand for enriched uranium is increasing, with industry participants and policymakers emphasizing the importance of bolstering domestic production to meet future energy needs.
- Positive Market Reaction: ASPI's stock rose 0.7% in Friday's premarket trading, and retail sentiment on Stocktwits shifted from 'bearish' to 'neutral', indicating growing market confidence in the company's future prospects.
See More
RedChip Show to Feature Interviews with TMC and ASPI
- TMC's Strategic Role: TMC CFO Craig Shesky emphasized the company's importance in addressing U.S. critical mineral dependence during the RedChip show, particularly through the development of polymetallic nodule resources in the Clarion Clipperton Zone, which could provide a long-term domestic supply of nickel, copper, cobalt, and manganese, thereby enhancing the U.S.'s strategic position amid geopolitical competition.
- Regulatory Framework Progress: Shesky noted TMC's advancements under the U.S. Deep Seabed Hard Mineral Resources Act and updates to NOAA's permitting process, which streamline the path toward commercial recovery, facilitating rapid growth in the critical minerals sector.
- ASPI's Market Positioning: ASP Isotopes CEO Paul Mann discussed the company's vertically integrated strategy to become a leading Western supplier of critical stable isotopes and nuclear fuels, highlighting the increasing importance of ASPI amid global supply concentration, particularly Russia's dominance in stable isotope production.
- Revenue Growth Potential: Mann pointed out that ASPI's nuclear medicine platform is generating double-digit year-over-year revenue growth, and the recent acquisition of Renergen provides access to one of the world's most concentrated helium resources, with 2026 poised to be a transformational year for the company as it advances toward scaled commercial production across multiple high-value critical material markets.
See More
Significant Progress in U.S. Nuclear Fuel Supply Chain
- Strategic Partnership: ASP Isotopes Inc.'s subsidiary Quantum Leap Energy has signed a non-binding MOU with a major U.S. energy company to evaluate options for supporting the establishment of advanced nuclear fuel cycle facilities in the U.S., thereby enhancing domestic nuclear fuel production capabilities.
- Nuclear Fuel Production Plans: Under the MOU, QLE plans to produce high assay low enriched uranium (HALEU) and low enriched uranium plus (LEU+), as well as provide uranium conversion and deconversion services, which will help meet the future demand for higher enrichment levels in small modular reactors, thus enhancing U.S. energy independence.
- Growing Market Demand: With the U.S. government planning to ban Russian uranium imports by 2028, the urgent need for domestic uranium enrichment capacity is increasing, and QLE's facilities are expected to fill a critical gap in the nuclear fuel supply chain, potentially having a profound impact on the future nuclear energy market.
- Technological Innovation and Collaboration: QLE is committed to accelerating the commercialization of critical isotopes through strategic partnerships with industry leaders, leveraging unique technological solutions to further advance U.S. competitiveness and innovation in the nuclear energy sector.
See More
Investigation into ASP Isotopes Inc. Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of ASP Isotopes Inc. (NASDAQ:ASPI) breached their fiduciary duties to shareholders, potentially impacting corporate governance.
- Legal Relief Options: Long-term shareholders of ASP stock may seek corporate governance reforms, return of funds, or court-approved financial incentive awards, which could improve management and transparency.
- Importance of Participation: Shareholder involvement can drive improvements in company policies, practices, and oversight mechanisms, enhancing transparency and accountability, ultimately increasing shareholder value.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, reducing the financial burden of participation.
See More
Shorepower Merges with Aeternum, Shifts Focus to Health Technologies
- Merger Agreement: Shorepower Technologies has signed a merger agreement with Aeternum Health, with Aeternum merging into Shorepower, which will shift its strategic focus to health optimization and longevity technologies, marking a significant change in the company's direction.
- Equity Structure Adjustment: Post-merger, the sole member of Aeternum Health will receive 51% of Shorepower's common stock, and 2 million shares of Series B Preferred Stock will be issued, each with voting power equivalent to 40 shares of common stock, enhancing the new management's control.
- Capital and Technology Injection: Aeternum will contribute at least $1.5 million in cash and intellectual property related to a novel peptide mix aimed at longevity and anti-aging, which is expected to enhance the company's competitive position in the market.
- Leadership Change: Following the merger, Jeff Kim will resign as President and CEO, with Paul E. Mann of Aeternum taking over, bringing over two decades of experience in biotechnology and healthcare investing, which is anticipated to open new growth opportunities for the company.
See More
